We are analyzing https://link.springer.com/article/10.1007/s00134-006-0183-9.

Title:
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose | Intensive Care Medicine
Description:
Objective To develop guidelines for the management of QT prolongation after citalopram overdose, including decontamination with single-dose activated charcoal (SDAC) and cardiac monitoring. Design Simulation study using a previously developed pharmacokinetic-pharmacodynamic (PKPD) model which predicted the time-course of QT prolongation and the effect of citalopram dose and use of SDAC on QT prolongation. Main measures and results The previously developed PKPD model was used to address the following in patients following citalopram overdose: (1) Above what dose should patients be decontaminated? (2) Above what dose should patients have cardiac monitoring? (3) For what period of time should patients be monitored? The primary outcome was QT,RR combinations above an abnormal threshold as a surrogate predictor of torsades de pointes. Simulations were performed using MATLAB for an overdose patient with typical demographics: 30-year-old female with a heart rate of 79 bpm taking citalopram therapeutically. The simulations showed: (1) There was significant benefit associated with the administration of SDAC to patients following citalopram overdose ingesting > 600 mg; (2) With citalopram overdoses > 1,000 mg it was advisable to give SDAC and cardiac monitor the patient; (3) The risk of developing future abnormal QT,RR combinations was less than 1% in patients with normal QT,RR combinations up to 13 h post-dose, so the minimum monitoring time for citalopram overdoses > 1,000 mg should be 13 h. Recommended dose levels for intervention should be lowered in older patients and patients with tachycardia, while men are less sensitive to QT prolongation. Conclusions Guidelines for the management of QT prolongation after citalopram overdose were developed. We believe the model will help clinicians to decide which patients to decontaminate and monitor.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Technology & Computing
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

article, citalopram, google, scholar, pubmed, cas, overdose, isbister, patients, prolongation, toxicol, clinical, pharmacokineticpharmacodynamic, management, friberg, interval, clin, privacy, cookies, content, data, research, modelling, duffull, dose, qtrr, drug, information, publish, search, geoffrey, sdac, cardiac, study, model, pointes, heart, access, subjects, med, pharmacol, log, journal, intensive, care, lena, guidelines, activated, charcoal, monitoring,

Topics {✒️}

month download article/chapter undertook pharmacokinetic-pharmacodynamic modelling previously developed pharmacokinetic-pharmacodynamic pharmacokinetic-pharmacodynamic modelling qt-rr interval relationship steady-state pharmacokinetics full article pdf clinical toxicology le couteur dg privacy choices/manage cookies related gene inhibition oral drug overdose multiple drug interactions randomized clinical trial single-dose activated charcoal article isbister related subjects qt interval prolongation european economic area torsades de pointes hospital pharmacist interventions chronic kidney disease relative toxicity acute coronary syndromes breast fed infants torsade de pointes balit cr high intrasubject stability alice wallenberg foundation newcastle mater hospital qt-rr relationship healthy subjects conditions privacy policy national data elements acta pharmacol toxicol recommended dose levels cardiac arrest [abstract] isbister gk accepting optional cookies heart rate correction citalopram overdose—review clinical study article log check access instant access journal finder publish develop guidelines conclusions guidelines population pharmacokinetics article cite

Questions {❓}

The previously developed PKPD model was used to address the following in patients following citalopram overdose: (1) Above what dose should patients be decontaminated?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose
         description:To develop guidelines for the management of QT prolongation after citalopram overdose, including decontamination with single-dose activated charcoal (SDAC) and cardiac monitoring. Simulation study using a previously developed pharmacokinetic-pharmacodynamic (PKPD) model which predicted the time-course of QT prolongation and the effect of citalopram dose and use of SDAC on QT prolongation. The previously developed PKPD model was used to address the following in patients following citalopram overdose: (1) Above what dose should patients be decontaminated? (2) Above what dose should patients have cardiac monitoring? (3) For what period of time should patients be monitored? The primary outcome was QT,RR combinations above an abnormal threshold as a surrogate predictor of torsades de pointes. Simulations were performed using MATLAB for an overdose patient with typical demographics: 30-year-old female with a heart rate of 79 bpm taking citalopram therapeutically. The simulations showed: (1) There was significant benefit associated with the administration of SDAC to patients following citalopram overdose ingesting > 600 mg; (2) With citalopram overdoses > 1,000 mg it was advisable to give SDAC and cardiac monitor the patient; (3) The risk of developing future abnormal QT,RR combinations was less than 1% in patients with normal QT,RR combinations up to 13 h post-dose, so the minimum monitoring time for citalopram overdoses > 1,000 mg should be 13 h. Recommended dose levels for intervention should be lowered in older patients and patients with tachycardia, while men are less sensitive to QT prolongation. Guidelines for the management of QT prolongation after citalopram overdose were developed. We believe the model will help clinicians to decide which patients to decontaminate and monitor.
         datePublished:2006-05-10T00:00:00Z
         dateModified:2006-05-10T00:00:00Z
         pageStart:1060
         pageEnd:1065
         sameAs:https://doi.org/10.1007/s00134-006-0183-9
         keywords:
            Citalopram
            Clinical guidelines
            Overdose
            Pharmacokinetic-pharmacodynamic modelling
            Simulation
            Toxicity
            Intensive / Critical Care Medicine
            Anesthesiology
            Emergency Medicine
            Pneumology/Respiratory System
            Pain Medicine
            Pediatrics
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00134-006-0183-9/MediaObjects/134_2006_183_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00134-006-0183-9/MediaObjects/134_2006_183_Fig2_HTML.gif
         isPartOf:
            name:Intensive Care Medicine
            issn:
               1432-1238
               0342-4642
            volumeNumber:32
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Geoffrey K. Isbister
               affiliation:
                     name:Charles Darwin University
                     address:
                        name:Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
                        type:PostalAddress
                     type:Organization
                     name:Newcastle Mater Hospital
                     address:
                        name:Department of Clinical Toxicology, Newcastle Mater Hospital, Waratah, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Lena E. Friberg
               affiliation:
                     name:University of Queensland
                     address:
                        name:School of Pharmacy, University of Queensland, Brisbane, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephen B. Duffull
               affiliation:
                     name:University of Queensland
                     address:
                        name:School of Pharmacy, University of Queensland, Brisbane, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose
      description:To develop guidelines for the management of QT prolongation after citalopram overdose, including decontamination with single-dose activated charcoal (SDAC) and cardiac monitoring. Simulation study using a previously developed pharmacokinetic-pharmacodynamic (PKPD) model which predicted the time-course of QT prolongation and the effect of citalopram dose and use of SDAC on QT prolongation. The previously developed PKPD model was used to address the following in patients following citalopram overdose: (1) Above what dose should patients be decontaminated? (2) Above what dose should patients have cardiac monitoring? (3) For what period of time should patients be monitored? The primary outcome was QT,RR combinations above an abnormal threshold as a surrogate predictor of torsades de pointes. Simulations were performed using MATLAB for an overdose patient with typical demographics: 30-year-old female with a heart rate of 79 bpm taking citalopram therapeutically. The simulations showed: (1) There was significant benefit associated with the administration of SDAC to patients following citalopram overdose ingesting > 600 mg; (2) With citalopram overdoses > 1,000 mg it was advisable to give SDAC and cardiac monitor the patient; (3) The risk of developing future abnormal QT,RR combinations was less than 1% in patients with normal QT,RR combinations up to 13 h post-dose, so the minimum monitoring time for citalopram overdoses > 1,000 mg should be 13 h. Recommended dose levels for intervention should be lowered in older patients and patients with tachycardia, while men are less sensitive to QT prolongation. Guidelines for the management of QT prolongation after citalopram overdose were developed. We believe the model will help clinicians to decide which patients to decontaminate and monitor.
      datePublished:2006-05-10T00:00:00Z
      dateModified:2006-05-10T00:00:00Z
      pageStart:1060
      pageEnd:1065
      sameAs:https://doi.org/10.1007/s00134-006-0183-9
      keywords:
         Citalopram
         Clinical guidelines
         Overdose
         Pharmacokinetic-pharmacodynamic modelling
         Simulation
         Toxicity
         Intensive / Critical Care Medicine
         Anesthesiology
         Emergency Medicine
         Pneumology/Respiratory System
         Pain Medicine
         Pediatrics
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00134-006-0183-9/MediaObjects/134_2006_183_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00134-006-0183-9/MediaObjects/134_2006_183_Fig2_HTML.gif
      isPartOf:
         name:Intensive Care Medicine
         issn:
            1432-1238
            0342-4642
         volumeNumber:32
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Geoffrey K. Isbister
            affiliation:
                  name:Charles Darwin University
                  address:
                     name:Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
                     type:PostalAddress
                  type:Organization
                  name:Newcastle Mater Hospital
                  address:
                     name:Department of Clinical Toxicology, Newcastle Mater Hospital, Waratah, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Lena E. Friberg
            affiliation:
                  name:University of Queensland
                  address:
                     name:School of Pharmacy, University of Queensland, Brisbane, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephen B. Duffull
            affiliation:
                  name:University of Queensland
                  address:
                     name:School of Pharmacy, University of Queensland, Brisbane, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Intensive Care Medicine
      issn:
         1432-1238
         0342-4642
      volumeNumber:32
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Charles Darwin University
      address:
         name:Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
         type:PostalAddress
      name:Newcastle Mater Hospital
      address:
         name:Department of Clinical Toxicology, Newcastle Mater Hospital, Waratah, Australia
         type:PostalAddress
      name:University of Queensland
      address:
         name:School of Pharmacy, University of Queensland, Brisbane, Australia
         type:PostalAddress
      name:University of Queensland
      address:
         name:School of Pharmacy, University of Queensland, Brisbane, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Geoffrey K. Isbister
      affiliation:
            name:Charles Darwin University
            address:
               name:Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
               type:PostalAddress
            type:Organization
            name:Newcastle Mater Hospital
            address:
               name:Department of Clinical Toxicology, Newcastle Mater Hospital, Waratah, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Lena E. Friberg
      affiliation:
            name:University of Queensland
            address:
               name:School of Pharmacy, University of Queensland, Brisbane, Australia
               type:PostalAddress
            type:Organization
      name:Stephen B. Duffull
      affiliation:
            name:University of Queensland
            address:
               name:School of Pharmacy, University of Queensland, Brisbane, Australia
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
      name:Department of Clinical Toxicology, Newcastle Mater Hospital, Waratah, Australia
      name:School of Pharmacy, University of Queensland, Brisbane, Australia
      name:School of Pharmacy, University of Queensland, Brisbane, Australia
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(84)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.09s.

LINK . SPRINGER . COM {}